Astrazeneca plc (AZN) RNS Announcements

Date	Time	Date	TitleTitle (filtered)	Source
12/11/19	07:00:12	12 Nov 2019	Anifrolumab demonstrated superiority in TULIP 2	Anifrolumab demonstrated superiority in TULIP 2	RNS
11/11/19	07:00:07	11 Nov 2019	Roxadustat pooled analyses: no increased CV risk	Roxadustat pooled analyses: no increased CV risk	RNS
08/11/19	07:00:02	8 Nov 2019	Roxadustat significantly increased haemoglobin	Roxadustat significantly increased haemoglobin	RNS
06/11/19	14:10:57	6 Nov 2019	Calquence data to show improved progression-free	Calquence data to show improved progression-free	RNS
01/11/19	15:00:05	1 Nov 2019	Total Voting Rights	Total Voting Rights	RNS
30/10/19	07:00:03	30 Oct 2019	AstraZeneca divests rights to Seroquel and	AstraZeneca divests rights to Seroquel and	RNS
28/10/19	15:31:44	28 Oct 2019	Imfinzi and Imfinzi plus tremelimumab delayed	Imfinzi and Imfinzi plus tremelimumab delayed	RNS
24/10/19	08:00:05	24 Oct 2019	AstraZeneca year-to-date and Q3 2019 results	AstraZeneca year-to-date and Q3 2019 results	RNS
21/10/19	08:00:07	21 Oct 2019	Farxiga approved in the US to reduce the risk of	Farxiga approved in the US to reduce the risk of	RNS
17/10/19	08:00:05	17 Oct 2019	Trastuzumab deruxtecan granted FDA Priority Review	Trastuzumab deruxtecan granted FDA Priority Review	RNS
04/10/19	16:04:03	4 Oct 2019	Holding(s) in Company	Holding(s) in Company	RNS
04/10/19	16:00:03	4 Oct 2019	Holding(s) in Company	Holding(s) in Company	RNS
04/10/19	08:00:04	4 Oct 2019	Fasenra approved in the US for self-administration	Fasenra approved in the US for self-administration	RNS
03/10/19	17:00:01	3 Oct 2019	Director Declaration	Director Declaration	RNS
01/10/19	16:00:01	1 Oct 2019	Total Voting Rights	Total Voting Rights	RNS
01/10/19	08:05:03	1 Oct 2019	AstraZeneca divests rights for Losec to Cheplaphar	AstraZeneca divests rights for Losec to Cheplaphar	RNS
01/10/19	08:00:15	1 Oct 2019	Update on US regulatory review of PT010 in COPD	Update on US regulatory review of PT010 in COPD	RNS
30/09/19	16:30:03	30 Sept 2019	Lynparza more than doubled the time without	Lynparza more than doubled the time without	RNS
30/09/19	08:00:21	30 Sept 2019	Tagrisso is the only 1st-line treatment for EGFR-	Tagrisso is the only 1st-line treatment for EGFR-	RNS
30/09/19	08:00:21	30 Sept 2019	Lynparza improved the time women lived without	Lynparza improved the time women lived without	RNS
23/09/19	08:00:11	23 Sept 2019	Qtrilmet recommended for approval in EU by CHMP	Qtrilmet recommended for approval in EU by CHMP	RNS
18/09/19	08:00:21	18 Sept 2019	AstraZeneca amends collaboration with Ironwood	AstraZeneca amends collaboration with Ironwood	RNS
04/09/19	08:11:18	4 Sept 2019	Tagrisso approved in China as a 1st-line treatment	Tagrisso approved in China as a 1st-line treatment	RNS
02/09/19	16:00:06	2 Sept 2019	Total Voting Rights	Total Voting Rights	RNS
02/09/19	08:05:02	2 Sept 2019	Brilinta reduced the risk of cardiovascular events	Brilinta reduced the risk of cardiovascular events	RNS
02/09/19	08:00:07	2 Sept 2019	Detailed results from Phase III DAPA-HF trial	Detailed results from Phase III DAPA-HF trial	RNS
29/08/19	08:00:07	29 Aug 2019	Anifrolumab Phase III trial meets primary endpoint	Anifrolumab Phase III trial meets primary endpoint	RNS
28/08/19	08:05:01	28 Aug 2019	Fasenra granted US Orphan Drug Designation for	Fasenra granted US Orphan Drug Designation for	RNS
28/08/19	08:00:04	28 Aug 2019	Breztri Aerosphere Phase III ETHOS trial met	Breztri Aerosphere Phase III ETHOS trial met	RNS
22/08/19	08:00:15	22 Aug 2019	Roxadustat approved in China for the treatment of	Roxadustat approved in China for the treatment of	RNS
22/08/19	08:00:09	22 Aug 2019	AstraZeneca agrees to buy US FDA Priority Review	AstraZeneca agrees to buy US FDA Priority Review	RNS
21/08/19	08:00:02	21 Aug 2019	Update on the Phase III NEPTUNE trial	Update on the Phase III NEPTUNE trial	RNS
20/08/19	08:00:11	20 Aug 2019	Farxiga met primary endpoint in landmark Phase III	Farxiga met primary endpoint in landmark Phase III	RNS
19/08/19	08:00:05	19 Aug 2019	Directorate Change	Directorate Change	RNS
14/08/19	08:00:08	14 Aug 2019	Lynparza Phase III PAOLA-1 trial met primary endpo	Lynparza Phase III PAOLA-1 trial met primary endpo	RNS
14/08/19	08:00:07	14 Aug 2019	Calquence granted US Breakthrough Therapy Designat	Calquence granted US Breakthrough Therapy Designat	RNS
09/08/19	10:28:52	9 Aug 2019	Amendment: Tagrisso significantly improves overall	Amendment: Tagrisso significantly improves overall	RNS
09/08/19	08:00:04	9 Aug 2019	Tagrisso significantly improves overall survival	Tagrisso significantly improves overall survival	RNS
07/08/19	08:00:06	7 Aug 2019	Lynparza Phase III PROfound trial in HRR*	Lynparza Phase III PROfound trial in HRR*	RNS
05/08/19	08:00:06	5 Aug 2019	Forxiga label updated in the EU in type-2 diabetes	Forxiga label updated in the EU in type-2 diabetes	RNS
01/08/19	16:00:01	1 Aug 2019	Total Voting Rights	Total Voting Rights	RNS
25/07/19	08:00:11	25 Jul 2019	AZN: H1 2019 Results	AZN: H1 2019 Results	RNS
16/07/19	08:00:08	16 Jul 2019	Operational Improvements and New Euskaltel CEO	Operational Improvements and New Euskaltel CEO	RNS
15/07/19	08:00:06	15 Jul 2019	Update on US regulatory decision for Farxiga	Update on US regulatory decision for Farxiga	RNS
12/07/19	08:00:03	12 Jul 2019	Imfinzi granted US Orphan Drug Designation for	Imfinzi granted US Orphan Drug Designation for	RNS
11/07/19	08:00:06	11 Jul 2019	Update on Zegona's Strategy for Euskaltel	Update on Zegona's Strategy for Euskaltel	RNS
01/07/19	16:00:01	1 Jul 2019	Total Voting Rights	Total Voting Rights	RNS
19/06/19	08:00:04	19 Jun 2019	Breztri Aerosphere (PT010) approved in Japan for	Breztri Aerosphere (PT010) approved in Japan for	RNS
19/06/19	08:00:04	19 Jun 2019	Lynparza approved in Japan for 1st-line	Lynparza approved in Japan for 1st-line	RNS
19/06/19	08:00:04	19 Jun 2019	Bevespi Aerosphere approved by the Japanese	Bevespi Aerosphere approved by the Japanese	RNS

Showing 751–800 of 1,436 announcements

Astrazeneca plc RNS

Astrazeneca plc RNS